Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 07, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 50,052 | $12.28 | 342,192 | |
| Jul 07, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 51,531 | -- | 28,469 | |
| Jul 07, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 64,601 | -- | 25,399 | |
| Jul 07, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 12,804 | -- | 69,840 | |
| Jul 07, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 50,052 | -- | 39,948 | |
| Jul 02, 2020 | Principal Accounting Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 198 | $10.04 | 1,733 | |
| Jul 02, 2020 | Principal Accounting Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 198 | -- | 5,940 | |
| Jul 01, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 12,500 | $6.06 | 351,264 | |
| Jul 01, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 12,500 | -- | 12,500 | |
| Jul 01, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | $5.96 | 920,023 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.